Is it Time to Take Your Profits From Viking Therapeutics Inc. [VKTX] Stock?

Over the past three months, Viking Therapeutics Inc. [VKTX] ended the trading day at $6.01 and exhibited a change of -1.17% with a 24 hour trading and reached upto the volume of 1.18M compared to its recorded trading volume of 0.56 million. VKTX generated a 1 year amount change with -17.17%. Though for Principal markets a year is counted as a long time period. By having a look at the most recent performance of this stock, in the last week its amount moved by -5.44% with an amount shift of -1.38% over the last month.

On 10, November 2020, Viking Therapeutics to Present at Stifel Healthcare Conference 2020. According to news published on Yahoo Finance, Viking Therapeutics, Inc. (“Viking”) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that its chief executive officer, Brian Lian, Ph.D., will deliver a corporate presentation as part of the Stifel Healthcare Conference 2020. The conference, which will take place November 16-18, 2020, is being conducted with a virtual format.

Analyst Birdseye View:

The most recent analyst activity for Viking Therapeutics Inc. [NASDAQ:VKTX] stock was on May 05, 2020, when it was Initiated with a Buy rating from Chardan Capital Markets, which also raised its 12-month price target on the stock to $15. Before that, on June 05, 2020, BMO Capital Markets Recapitulated an Outperform rating and elevated its amount target to $14. On May 01, 2020, BTIG Research Initiated a Buy rating and boosted its price target on this stock to $9. On July 16, 2019, Oppenheimer Initiated an Outperform rating and increased its price target to $12. On June 25, 2019, Stifel Initiated a Buy rating. On March 29, 2019, SVB Leerink Upgrade an Outperform rating and boosted its amount target on this stock to $21. On March 14, 2019, Maxim Group Reiterated a Buy rating and decreased its target amount on this stock from $28 to $20.

In the past 52 weeks of trading, this stock has oscillated between a low of $3.26 and a peak of $8.87. Right now, according to Wall Street analyst the average 12-month amount target is $19.62. At the most recent market close, shares of Viking Therapeutics Inc. [NASDAQ:VKTX] were valued at $6.01.

FUNDAMENTAL ANALYSIS

If looking now at the Principal structure of this organization, it shows its whole liability to the whole Principal at 0.24 and the whole liability to whole assets at 0.23. It shows enduring liability to the whole principal at 0.13 and enduring liability to assets at 0.00 while looking for an extended time period.

Readers are usually of view to make a close observation to the indicators that support and make resistance before moving to any particular stock. As of now, the company’s stock is sitting at 5.93 points at 1st support level, the second support level is making up to 5.77. But as of 1st resistance point, this stock is sitting at 6.36 and at 6.63 for 2nd resistance point.

Viking Therapeutics Inc. [VKTX] reported its earnings at -$0.13 per share in the fiscal quarter closing of 9/29/2020. The Analysts for Wall Street were expecting to report its earnings at -$0.15/share signifying the difference of 0.02 and 13.30% surprise value. Comparing the previous quarter ending of 6/29/2020, the stated earnings were -$0.13 calling estimates for -$0.14/share with the difference of 0.01 depicting the surprise of 7.10%.

Important Ratio’s To Watch

Meanwhile, turning our focus to liquidity, the Current Ratio for Viking Therapeutics Inc. [NASDAQ:VKTX] is 27.10. Likewise, the Quick ratio is also the same, showing Cash ratio at 40.67. Now if looking for a valuation of this stock’s amount to book ratio is 2.10.

Insider Stories

The most recent insider trade was by LIGAND PHARMACEUTICALS INC, 10% Owner, and it was the sale of 94488.0 shares on Aug 26. LIGAND PHARMACEUTICALS INC, the 10% Owner, completed a sale of 70000.0 shares on Aug 25. On Jun 30, FOEHR MATTHEW W, Director, completed a sale of 13000.0 shares.